Thyroid disorders (TDs), typically associated with anti-PD-1 antibodies and hypophysitis (IH) commonly related to anti-CTLA-4 therapy, are the most frequent endocrine toxicities. This evidence concerns the gene CTLA4 and isolated hemihyperplasia.